One price in Japan, response-linked payments in Australia, no public price in China: CAR-T sponsors face three markets.
QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 … Read more
Regeneration programmes can make axons grow. If targeting is transcriptional, growth was always the achievable half of a two-part problem.
Pasatru’s flare benefit is clinician-assessed only. GENGLYCOS is indicated to reduce cornstarch intake. Two firsts, both measured a step from the patient.
Five mitochondrial drug classes named for CAR-T neurotoxicity, and the authors say none is under formal investigation. Every one is generic or preclinical.
Two carriers built new pharma lanes in five weeks. Both end at Heathrow, an airport that lost a day to one transformer fire in March 2025.
No bespoke regime is coming. Microbiome medicines meet the standard biological bar in the UK, while the EU builds a separate SoHO framework.
CBER took a 24% response in 91 evaluable patients, one day after the same committee voted nine to three against Capricor. Measurement, not size.
The ballot was the outcome. A drug’s strongest dataset sitting off the voting question is not a footnote, it is the whole result.
J&J committed $785 million including a $465 million equity stake, plus an option to acquire Sail Biomedicines for $2.58 billion, on a preclinical in vivo CAR-T platform.